Search for Clinical Trial Results

Sponsored By

Neuromyelitis Optica Spectrum Disorder - 4 Studies Found

Status Study
NOT_YET_RECRUITING Study Name: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA� During Pregnancy
Condition:
Date: 2025-07-19
Interventions: Enrolled female participants with NMOSD who were exposed to UPLIZNA during pregnancy will be assessed.No study drug will be administered.
NOT_YET_RECRUITING Study Name: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
Condition:
Date: 2025-07-19
Interventions: Inebilizumab: 300mg IV on Day1 and Day 15.The first dose of inelizumab is given during IVMP.
COMPLETED Study Name: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Condition: Neuromyelitis Optica Spectrum Disorder
Date: 2025-07-19
Interventions: IV, once every 12 weeks (Q12W)
COMPLETED Study Name: BLAZE-Limiting Approach in NMOSD
Condition: Neuromyelitis Optica Spectrum Disorders (NMOSD)
Date: 2025-07-19
Interventions: Eculizumab was administered intravenously at a dosage of 900 mg weekly for four consecutive weeks